The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of common shares by the selling securityholders. The company stated: “The common shares being offered by this prospectus represent vastly more than the number of our outstanding common shares, and the sales of such common shares, or the perception that those sales might occur, could depress the market price of our common shares and could impair our ability to raise capital through the sale of additional equity securities.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Optimi Health, Psyence Biomedical sign LOI for psilocybin drug development
- Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
- Psyence Biomedical enters $25M common stock purchase agreement with White Lion
- Psyence Biomedical Announces $25M Stock Sale Deal
- Psyence Group provides update on Filament Health commercial licensing agreement